Skip to content
Screener

Relay Therapeutics, Inc. RLAY Total Liabilities & Equity

Total Liabilities & Equity at other companies

Schrodinger logo
SchrodingerSDGR
$640.39M-7.0%
PVL
Palvella TherapeuticsPVLA
$263.76M+232%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$1.21B-6.9%
Celcuity logo
CelcuityCELC
$410.16M+88.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$4.32B+77.9%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$2.19B+130%

Other financials

Income statement

See full
Revenue$350.0K-48.3%
Operating income-$90.8M-18.2%
Net income-$83.7M-18.9%
EPS (diluted)-$0.410.0%

Balance sheet

See full
Cash & equivalents$121.2M+6.4%
Total debt$30.7M-10.3%
Total equity$890.0M+33.7%
Total assets$967.5M+32.7%

Cash flow

See full
Operating cash flow-$54.1M+2.1%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$4.3B+611%
Enterprise value$4.21B+702%
P/S415.9×+343×

Profitability

See full
Operating margin-2,999.4%-637pp
Net margin-2,763.6%-568pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-36.8%-6.3pp
Debt / equity0.0×
Current ratio18.3×-2.7×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338056
Line itemJune 30, 2026December 31, 2025
Stockholders’ equity:
Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 450,000,000 and 300,000,000 shares authorized as of June 30, 2026, and December 31, 2025, respectively; 218,531,200 and 173,868,949 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively211168
Additional paid-in capital3,063,1182,580,928
Accumulated other comprehensive (loss) gain(1,553)733
Accumulated deficit(2,171,767)(2,014,769)
Total stockholders’ equity890,009567,060
Total liabilities and stockholders’ equity$967,457$621,331

Item 1. Financial Statements.

FAQ

What is Relay Therapeutics, Inc.'s total liabilities & equity?
Relay Therapeutics, Inc. (RLAY) reported total liabilities & equity of $967.46M in Q2 2026.
How has Relay Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Relay Therapeutics, Inc.'s total liabilities & equity increased by 32.7% year-over-year, from $728.84M to $967.46M.
What is the long-term trend for Relay Therapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s total liabilities & equity has grown at a -4.9% compound annual growth rate (CAGR), from $799.83M to $621.33M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Relay Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude